Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
March 11, 2019
IRVINE, Calif., -- Edwards Lifesciences Corporation EW, -0.99% the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two... Learn More
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
February 25, 2019
Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis Claims have... Learn More
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
January 22, 2019
VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES 42.9% of VOS subjects vs 18.4% of Restasis® subjects (p=.0055) demonstrated ≥ 10mm improvement in STT... Learn More
January 17, 2019
VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a new... Learn More
Our investment team of 9 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
“Lumira’s philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael’s ability to accelerate the pace.”
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael’s Hospital
“Lumira’s model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation.”
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3, Place Ville Marie
Bureau 12350, Niveau L
Canada, H3B 0E7
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street